H-Index
14
Scimago Lab
powered by Scopus
eISSN: 1941-5923
call: +1.631.629.4328
Mon-Fri 10 am - 2 pm EST

Logo


Call for COVID-19 Case Reports                                                                                                                                                                Priority Code: COVID-19

At this time, the American Journal of Case Reports is particularly interested in publishing reports that demonstrate informative aspects of cases of coronavirus disease 2019 (COVID-19) due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2).

We hope to encourage submissions from authors worldwide who may be reluctant to submit publications at this time due to article processing costs. Therefore, the American Journal of Case Reports is offering a 50% reduction of publishing costs and priority processing of all case reports and case series on aspects of COVID-19 that are accepted for publication following peer-review (Priority Processing & Discount Code: COVID-19).

During this global pandemic, and as clinical experience of this new viral infection continues to accumulate, the global medical community can play an important role by sharing clinical experience through case reports and case series. 

Details of submission of manuscripts for the American Journal of Case Reports, and a manuscript template in Word, are available from: https://www.amjcaserep.com/instructions


Published: 2020-06-04

Sustained Virologic Suppression After 4 Weeks of Ledipasvir/Sofosbuvir in Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Co-Infection

Joshua P. Havens, Nichole N. Regan, Sara H. Bares

(Department of Internal Medicine, Infectious Diseases, University of Nebraska Medical Center, Omaha, NE, USA)

Am J Case Rep 2020; 21:e923326

DOI: 10.12659/AJCR.923326


BACKGROUND: Short-course hepatitis C (HCV) treatment with direct-acting antivirals (DAA) under 8 weeks in duration has resulted in variable efficacy rates in HCV mono-infection. Further, DAA courses under 8 weeks in duration have not been studied in HIV/HCV co-infection. We present a case report of 12-week sustained virologic suppression after treatment interruption of ledipasvir/sofosbuvir at 4 weeks in a patient with HIV/HCV co-infection.
CASE REPORT: A 28-year-old male patient diagnosed with well-controlled HIV infection and HCV co-infection (treatment-naïve, genotype 1a, unknown hepatic fibrosis) started a 12-week course of ledipasvir/sofosbuvir (LDV/SOF) for HCV treatment. The patient completed only 4 weeks of LDV/SOF before returning for follow-up 7 weeks after initiation. Ledipasvir/sofosbuvir treatment was discontinued. Sustained virologic suppression at 12 weeks was observed after completion of a short, 4-week course of LDV/SOF.
CONCLUSIONS: Compared to currently recommended treatment durations, clinical trials of short-course DAA treatments of less than 8 weeks have not demonstrated successful rates of SVR12. However, in cases of DAA interruption or incomplete treatment, clinicians may choose to assess for SVR12 prior to continuing or restarting the full treatment course.

Keywords: Antiviral Agents, Hepatitis C, HIV Infections



Related Articles (0)

Coming Soon...

Published: 2020-06-03

Rare Extracardiac Anomalies Presented with Right Heterotaxy Syndrome in a Newborn Baby: A Case Report


Roya Huseynova, Latifa A. Bin Mahmoud, Eman AlJohani, Oqtay Huseynov, Adli Abdelrahim, Khalid A. AlOmran

Am J Case Rep 2020; 21:e923341

DOI: 10.12659/AJCR.923341

Published: 2020-06-03

Combined Timed Surgery and Conservative Management of Primary Necrotizing Fasciitis of the Breast: A Case...


Concetta Anna Dodaro, Antonio Zaffiro, Anna Maria Iannicelli, Ludovica Giordano, Luigi Sorbino, Francesco Mangiapia, Mariangela Lanzano, Fabrizio Schonauer

Am J Case Rep 2020; 21:e922688

DOI: 10.12659/AJCR.922688